Beta Drugs Limited expands portfolio with Bevacizumab (ADCIMIB) and Trastuzumab (VICENTRA) biosimilars

New Delhi: Beta Drugs Limited (Adley Group), is a leading pharmaceutical company committed to providing innovative healthcare solutions. Is foraying into the biosimilars market with the introduction of biosimilar versions of two highly sought-after drugs: Bevacizumab and Trastuzumab. Both these Mabs are having about 640 cr market in India.

Beta Drugs Limited holds a strong position in the cytotoxic market. This strategic expansion underscores the company’s dedication to improving patient access to high-quality and affordable biologic therapies. The company believes that these biosimilars will play a vital role in expanding access to essential therapies for patients facing cancer and other related conditions.

Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has demonstrated remarkable efficacy in the treatment of various cancers, including Colorectal, Lung, and Kidney Cancer. Trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), is primarily used in the treatment of HER2-positive Breast Cancer. By introducing biosimilars of these critical drugs, the company aims to address the growing demand for cost-effective treatment options without compromising therapeutic outcomes.

With the introduction of biosimilars, the company reaffirms its dedication to improving the lives of patients and advancing healthcare outcomes.

Beta drugs ltd (Adley Group) always focuses on improving patient outcomes by optimizing therapeutic effectiveness. The company boasts a dedicated team of scientists focusing on developing of complex cancer drugs & enhancing drug delivery efficiency, particularly New Drug Delivery System (NDDS) formulation, and targeted therapies.
The company has already developed NDDS like Albumin bound Paclitaxel, Azacitidine oral tablets, Enzalutamide 160mg, Docetaxel & Gemcitabine RTU. Also, developed targeted therapy drugs like Dasatinib, Palbociclib, Nilotinib, and Rucaparib.

The company possesses a robust pipeline of first-to-launch New Drug Delivery System (NDDS) products. The company expects to launch at least six new molecules or NDDS formulations in FY 23-24. With its strong pipeline of first-to-launch NDDS products, the company is poised for continued success and growth. The company's relentless pursuit of innovation, deep understanding of patient needs, and scientific advancements, position it as a leader in the oncology landscape.